Month: January 2017
Occasionally I have been told that FDA reform is something that only a few libertarian economists support. But in fact, there is strong support for reform in much of the medical community. See, for example, the survey that Dan Klein and I did on off-label prescribing and FDA reform or the many surveys of physicians done by CEI.
I mentioned Dr. Vincent DeVita in my post, Will Trump Appoint a Great FDA Commissioner? It’s worthwhile exploring DeVita’s views at greater length because he is a prominent figure in the field of oncology. Here, from Wikipedia, is some background on DeVita:
Vincent Theodore DeVita, Jr., MD is an internationally recognized pioneer physician in the field of oncology. DeVita spent the early part of his career at the National Cancer Institute (NCI). In 1980, the president of the United States appointed him as director of the NCI and the National Cancer Program, a position he held until 1988. While at the NCI, he was instrumental in developing combination chemotherapy programs that ultimately led to an effective regimen of curative chemotherapy for Hodgkin’s disease and diffuse large cell lymphomas. Along with colleagues at the NCI, he developed the four-drug combination, known by the acronym MOPP, which increased the cure rate for patients with advanced Hodgkin’s disease from nearly zero to over 70%.
DeVita was the Director of Yale Cancer Center from 1993 to 2003. He is currently the chair of the Yale Cancer Center advisory board and is professor of internal medicine and of epidemiology and public health at Yale’s medical school.
DeVita currently serves on the editorial boards of numerous scientific journals and is the author or co-author of more than 450 scientific articles. He is one of the three editors of the popular textbook (also available online) Cancer: Principles and Practice of Oncology and serves as the editor-in-chief of The Cancer Journal.
In his book, The Death of Cancer, DeVita has a chapter on the FDA. The title of that chapter? Frances Kelsey Syndrome. He writes:
The thalidomide episode sent the message to those who worked at the FDA that the way to do right by people was to say no. Saying yes would prove perilous–not only to patients, but to the careers of a reviewer. As a result, the agency tends to reward those who say no, not yes. (In fact, there’s an annual Frances Kelsey award. But there are no awards for getting a good drug quickly into the public domain.)
Exactly right. Later he discusses another problem that he sees with FDA evaluation procedures:
We are approaching what we might have considered nirvana years ago. We can design drugs that will hit a specific target, and by being so specific, they have fewer side effects. But because effective treatments almost always require hitting more than one target at the same time, some very good and relatively safe cancer drugs show no evidence of effectiveness when used alone.
What a dilemma. After spending millions of dollars developing a drug, a company may be forced to abandon it for lack of efficacy, when, if approved, it would be another exciting tool for clinical investigators who want to explore combinations of targeted therapies in post-market research trials. Compound that with the FDA’s insistence on testing them first on patients with very advanced, resistant disease, and many potentially useful drugs don’t look so good. As a result, drug companies are reluctant to invest money in new cancer drugs, because they might never make it past the FDA’s hurdles.
DeVita may be wrong but he’s certainly not uninformed.
Several recent theories emphasize the negative effects of an aging population on economic growth, either because of the lower labor force participation and productivity of older workers or because aging will create an excess of savings over desired investment, leading to secular stagnation. We show that there is no such negative relationship in the data. If anything, countries experiencing more rapid aging have grown more in recent decades. We suggest that this counterintuitive finding might reflect the more rapid adoption of automation technologies in countries undergoing more pronounced demographic changes, and provide evidence and theoretical underpinnings for this argument.
This is not the final word, but it is interesting to see that the expected effect does not materialize.
I am wondering, by the way, if I might not cover all the requests you made in response to that post, except of course the ones I already have done in the past.
Got an advance copy. Between my non-manual-labor job, Netflix’s excellent recommendations (The OA is so good), and virtue-signaling to my in-group on Twitter, I guess I just wasn’t feeling it.
Besides, if I did read The Complacent Class, I’d have to write a review. The review would introduce readers to a bunch of new and challenging ideas about how Americans are losing the desire to embrace rapid change, and then I would explore some of the unexpected ways our complacency hurts us as a country, possibly challenging the author, or adding to his thesis with my own insights. Oh, people say they want new and challenging ideas, but they don’t. They’re happy with their current ideas, and why should I make anyone unhappy? No one ever considers whether the boat wants to be rocked.
Or is that Cowen’s game? To point out that our lack of urgency and general NIMBY-ism have led to less migration, more segregation, more inequality, dulled creativity, increased conformity, and faded activism, all of which portends a coming unavoidable chaos? What’s he after? Is Cowen trying to jolt us out of our zombie states so we can live in the sci-fi future of no diseases and flying cars and robot monkey butlers we all dreamed about when we were kids? I don’t know, man. Maybe. Anything’s possible, right? I literally didn’t read the book.
The tweet subtitle they gave my latest Bloomberg column:
Reading articles from other perspectives isn’t enough. Try writing one.
My final tag line:
We all need to worry about our own growing grumpiness.
5. Libertarian Bob Luddy builds low-cost private schools for the masses (video). I visited not long ago and was very impressed, I hope this can work out.
6. There is now a Marginal Revolution community on CommonLounge, I hope this can work out.
That is the topic of my latest Bloomberg column, here is only part of the argument, this one you really do need to read the whole thing (and carefully):
Trump’s supporters are indeed correct to point out that previous administrations also told many lies, albeit of a different sort. Imagine, for instance, that mistruths come in different forms: higher-status mistruths and lower-status mistruths. The high-status mistruths are like those we associate with ambassadors and diplomats. The ambassador is reluctant to tell a refutable, flat-out lie of the sort that could cause embarrassment, but if all you ever heard were the proclamations of the ambassador, you wouldn’t have a good grasp of the realities of the situation. Ambassadors typically are speaking to more than one audience at once, a lot of context is required to glean the actual meaning, and if they are interpreted in a strictly literal manner (a mistake) it is easy enough to find lots of misdirection in their words. Most of all, ambassadors just won’t voice a lot of sensitive truths.
Arguably those diplomatic proclamations are not lies, but they do bear quite an indirect relationship to the blunt, bare truth. Ambassadors and diplomats behave this way because they seek maximum flexibility in maintaining delicate coalitions of support over the longer run. And indeed it is correct to think of every incoming (and ongoing) administration of doing lots of “lying” — if that is the right word — of this sort.
These higher-status lies are not Trump’s style, and thus many of his supporters, with some justification, see him as a man willing to voice important truths. If Trump’s opponents don’t understand that reality, and the sociological differences between various kinds of misdirection, they are going to underestimate his appeal and self-righteously underestimate how much they are themselves mistrusted by the public.
Again, link here.
As I noted in yesterday’s post, Will Trump Appoint a Great FDA Commissioner?, personalized medicine is a challenge to the FDA. Technology Review has an excellent piece on an extreme version of personalized medicine, DIY gene therapy:
Hanley, 60, is the founder of a one-man company called Butterfly Sciences, also in Davis. After encountering little interest from investors for his ideas about using DNA injections to help strengthen AIDS patients, he determined that he should be the first to try it. “I wanted to prove it, I wanted to do it for myself, and I wanted to make progress,” says Hanley.
Most gene therapy involves high-tech, multimillion-dollar experiments carried out by large teams at top medical centers, with an eye to correcting rare illnesses like hemophilia. But Hanley showed that gene therapy can be also carried out on the cheap in the same setting as liposuction or a nose job, and might one day be easily accessed by anyone.
…Hanley opted instead for a simpler method called electroporation. In this procedure, circular rings of DNA, called plasmids, are passed into cells using an electrical current. Once inside, they don’t become a permanent part of person’s chromosomes. Instead, they float inside the nucleus. And if a gene is coded into the plasmid, it will start to manufacture proteins. The effect of plasmids is temporary, lasting weeks to a few months.
Hanley’s method is painful and doesn’t last long but it’s remarkable that it can be done at all.
At least one additional person who underwent self-administered gene therapy is a U.S. biotech executive who did not want his experience publicly known because he is dealing with the U.S. Food and Drug Administration on other matters.
Hanley says he did not secure the approval of the FDA before carrying out his experiment either. The agency requires companies to seek an authorization called an investigational new drug application, or IND, before administering any novel drug or gene therapy to people. “They said ‘You need an IND’ and I said, ‘No, I don’t,’” recalls Hanley, who traded e-mails with officials at the federal agency. He argued that self-experiments should be exempt, in part because they don’t pose any risk to the public.
Hat tip: Samir Varma.
Mike Lee says yes, see also Matt. Maybe, I would like to go this route, but I’m not (yet?) convinced. What if non-profits and foreign companies end up as the shareholders, as indeed the Coase theorem would seem to indicate? Doesn’t that lower tax revenue because they wouldn’t be making capital gains filings? And to some extent, isn’t the U.S. tax system then encouraging inefficient ownership and governance?
There may be an answer to this worry, but I’ve yet to see it.
That is a request from an MR reader. Getting past the “because I am weird” answer, I will offer a few observations:
1. I think my view, or broadly speaking some version of it, is in fact pretty popular,though far from dominant.
2. The eating and dining of many people is geared toward socializing and also drinking. So when I write “go where the diners look grim, not smiling and happy,” or “avoid the beautiful women and the riverfront views,” many people don’t listen. They like beautiful women, too much perhaps, and they like being surrounded by smiling others. I have more of a single-minded obsession on the food, at least when I am seeking food. So you can think of my methods as a form of extreme compartmentalization and unbundling of quests.
Of course there may be other methods related to beautiful women, and yes you should hold a diverse portfolio of methods, so think of me as someone who is suspicious of “method-blending,” as instead I prefer an intertemporal substitution of methods for different goals. The time for food is a time for food, not for pursuing some weighted average of goals summed into a mediocre total, “…and a time to every purpose under heaven.” Call it the Ecclesiastes approach. Ultimately this may involve preferring a certain kind of focus over indiscriminate attention-switching.
NB: This hypothesis also may imply that those who are good at intertemporal substitution may miss out on some of life’s integrative experiences, such as riding a bicycle along a bridge with the wind blowing in your hair; “intertemporal substitution” and “integration” may in some ways stand in tension, and perhaps developing a propensity for one limits our ability to engage in the other.
3. My dining methods are in fact wonderful for socializing, but only if you are with either a) the oblivious, b) those who lexically prefer food quality, or c) those who enjoy talking analytically about food. Most of my friends fall into one of these categories, but that is not the case for most people.
San Francisco, population 865,000, has roughly the same number of dogs as children: 120,000. In many areas of the city, pet grooming shops seem more common than schools.
There is also this:
San Francisco’s public school system has around 53,000 students, a sharp drop from 90,000 in 1970.
The decline is a reflection both of families leaving the city and wealthier parents sending their children to private schools. Around 30 percent of San Francisco children attend private school, the highest rate among large American cities.
More than 10 private schools have opened in San Francisco since 2009, according to a tally by Elizabeth Weise, a journalist who writes a blog on the subject.
What percentage of those people also support the idea of further experimentation with school vouchers? And do they require proof that private schools will raise their children’s test scores, before becoming emotionally committed to sending them there?
As someone who has written about FDA reform for many years it’s gratifying that all of the people whose names have been floated for FDA Commissioner would be excellent, including Balaji Srinivasan, Jim O’Neill, Joseph Gulfo, and Scott Gottlieb. Each of these candidates understands two important facts about the FDA. First, that there is fundamental tradeoff–longer and larger clinical trials mean that the drugs that are approved are safer but at the price of increased drug lag and drug loss. Unsafe drugs create concrete deaths and palpable fear but drug lag and drug loss fill invisible graveyards. We need an FDA commissioner who sees the invisible graveyard.
Each of the leading candidates also understands that we are entering a new world of personalized medicine that will require changes in how the FDA approves medical devices and drugs. Today almost everyone carries in their pocket the processing power of a 1990s supercomputer. Smartphones equipped with sensors can monitor blood pressure, perform ECGs and even analyze DNA. Other devices being developed or available include contact lens that can track glucose levels and eye pressure, devices for monitoring and analyzing gait in real time and head bands that monitor and even adjust your brain waves.
The FDA has an inconsistent even schizophrenic attitude towards these new devices—some have been approved and yet at the same time the FDA has banned 23andMe and other direct-to-consumer genetic testing companies from offering some DNA tests because of “the risk that a test result may be used by a patient to self-manage”. To be sure, the FDA and other agencies have a role in ensuring that a device or test does what it says it does (the Theranos debacle shows the utility of that oversight). But the FDA should not be limiting the information that patients may discover about their own bodies or the advice that may be given based on that information. Interference of this kind violates the first amendment and the long-standing doctrine that the FDA does not control the practice of medicine.
Srinivisan is a computer scientist and electrical engineer who has also published in the New England Journal of Medicine, Nature Biotechnology, and Nature Reviews Genetics. He’s a co-founder of Counsyl, a genetic testing firm that now tests ~4% of all US births, so he understands the importance of the new world of personalized medicine.
The world of personalized medicine also impacts how new drugs and devices should be evaluated. The more we look at people and diseases the more we learn that both are radically heterogeneous. In the past, patients have been classified and drugs prescribed according to a handful of phenomenological characteristics such as age and gender and occasionally race or ethnic background. Today, however, genetic testing and on-the-fly examination of RNA transcripts, proteins, antibodies and metabolites can provide a more precise guide to the effect of pharmaceuticals in a particular person at a particular time.
Greater targeting is beneficial but as Peter Huber has emphasized it means that drug development becomes much less a question of does this drug work for the average patient and much more about, can we identify in this large group of people the subset who will benefit from the drug? If we stick to standard methods that means even larger and more expensive clinical trials and more drug lag and drug delay. Instead, personalized medicine suggests that we allow for more liberal approval decisions and improve our techniques for monitoring individual patients so that physicians can adjust prescribing in response to the body’s reaction. Give physicians a larger armory and let them decide which weapon is best for the task.
I also agree with Joseph Gulfo (writing with Briggeman and Roberts) that in an effort to be scientific the FDA has sometimes fallen victim to the fatal conceit. In particular, the ultimate goal of medical knowledge is increased life expectancy (and reducing morbidity) but that doesn’t mean that every drug should be evaluated on this basis. If a drug or device is safe and it shows activity against the disease as measured by symptoms, surrogate endpoints, biomarkers and so forth then it ought to be approved. It often happens, for example, that no single drug is a silver bullet but that combination therapies work well. But you don’t really discover combination therapies in FDA approved clinical trials–this requires the discovery process of medical practice. This is why Vincent DeVita, former director of the National Cancer Institute, writes in his excellent book, The Death of Cancer:
When you combine multidrug resistance and the Norton-Simon effect , the deck is stacked against any new drug. If the crude end point we look for is survival, it is not surprising that many new drugs seem ineffective. We need new ways to test new drugs in cancer patients, ways that allow testing at earlier stages of disease….
DeVita is correct. One of the reasons we see lots of trials for end-stage cancer, for example, is that you don’t have to wait long to count the dead. But no drug has ever been approved to prevent lung cancer (and only six have ever been approved to prevent any cancer) because the costs of running a clinical trial for long enough to count the dead are just too high to justify the expense. Preventing cancer would be better than trying to deal with it when it’s ravaging a body but we won’t get prevention trials without changing our standards of evaluation.
Jim O’Neill, managing director at Mithril Capital Management and a former HHS official, is an interesting candidate precisely because he also has an interest in regenerative medicine. With a greater understanding of how the body works we should be able to improve health and avoid disease rather than just treating disease but this will require new ways of thinking about drugs and evaluating them. A new and non-traditional head of the FDA could be just the thing to bring about the necessary change in mindset.
In addition, to these big ticket items there’s also a lot of simple changes that could be made at the FDA. Scott Alexander at Slate Star Codex has a superb post discussing reciprocity with Europe and Canada so we can get (at the very least) decent sunscreen and medicine for traveler’s diarrhea. Also, allowing any major pharmaceutical firm to produce any generic drug without going through a expensive approval process would be a relatively simply change that would shut down people like Martin Shkreli who exploit the regulatory morass for private gain.
The head of the FDA has tremendous power, literally the power of life and death. It’s exciting that we may get a new head of the FDA who understands both the peril and the promise of the position.
J., a loyal MR reader, asked me for a post on “proliferation and separately nuclear exchange (war).”
Let’s try the latter. Every now and then I ask myself what is the most likely use of nuclear weapons, putting aside dirty bombs from terrorists and the like.
My first pick is a scenario where North Korea bombs a Japanese city, perhaps Hiroshima or Nagasaki. Imagine a North Korean regime in the throes of desperation, actually somewhat rational, and playing a mixed strategy with some probability of nuclear weapons use. Say the bluff is called and they feel a need to make a statement. I don’t think they would bomb their brethren in South Korea, nor would they opt for China, which could crush them like a bug. Japan, still perceived as a historic enemy by the way, is the obvious target. It’s close enough to reach, and they don’t have nuclear weapons of their own. Tokyo however must be held in reserve as a target, so Hiroshima or Nagasaki it would be. “Just big enough to send a message” — sound familiar?
My second pick is a scenario where the United States and China are fighting a naval battle in the South China Sea, or perhaps further north, as part of a limited exchange, not a full war. The United States is about to win the battle, and the Chinese leadership fears a military or other Party-based coup in response. So they use nuclear weapons, perhaps tactical nukes, to turn the tide in the battle and save their skins. They figure the U.S. won’t respond with a full-blown nuclear war. (America, if it lost a comparable naval battle, is more likely to just turn tail and run, at least in the short run.)
Fortunately, the chances of either of these events are quite low. Unfortunately, the chances are also rising somewhat.
There is more noise as of late coming from the India vs. Pakistan side (Pakistan threatening to use nukes to respond to a ground invasion, plus Pakistan having a nuclear submarine), but I don’t see actual evidence that the chance of nuclear war there has gone up. It has to make the list, but it’s not one of my top two scenarios.
My core model, by the way, is that political leaders are rational in the loose sense. So if you are looking for instances of possible nuclear weapons use, consider cases where politicians might be facing relatively dramatic “career-ending” events if they lose a smaller-level struggle.
3. “One of the Obama administration’s signature efforts in education, which pumped billions of federal dollars into overhauling the nation’s worst schools, failed to produce meaningful results, according to a federal analysis.” Link here. In 2003 I wrote that vouchers are overrated, but now they are definitely underrated.
Written by John Ferejohn and Frances McCall Rosenbluth, with the subtitle War, Peace, and the Democratic Bargain, this is a very important book. Here is the main thesis:
If the modern democratic republic is a product of wars that required both manpower and money for success, it is time to take stock of what happens to democracy once the forces that brought it into being are no longer present. Understanding war’s role in the creation of the modern democratic republic can help us recognize democracy’s exposed flanks. If the role of the masses in protecting the nation-state diminishes, will the cross-class coalition between political inclusiveness and property hold?
…a second question is what is to become of the swaths of the world that were off the warpath in the fourteenth and fifteenth centuries when the European state was formed? Continued and intense warfare forged democracies with full enfranchisement and protected property rights in the Goldilocks zone: in countries that had already developed administrative capacity as monarchies, and where wars were horrendous but manageable with full mobilization…
The bad news is that in today’s world, war has stopped functioning as a democratizing force.